Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ETHRIL 500 vs BIAXIN XL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen (paracetamol) is a central analgesic and antipyretic agent whose exact mechanism is not fully understood but is thought to involve inhibition of cyclooxygenase (COX) enzymes in the brain, primarily COX-2, and activation of descending serotonergic pathways. It has weak peripheral anti-inflammatory activity.
Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Mild to moderate pain,Fever
Acute bacterial exacerbation of chronic obstructive pulmonary disease,Acute maxillary sinusitis,Community-acquired pneumonia,Pharyngitis/tonsillitis caused by Streptococcus pyogenes,Uncomplicated skin and skin structure infections,Mycobacterium avium complex infection (prevention and treatment),Helicobacter pylori infection (in combination with other drugs)
500 mg orally every 6 hours as needed for pain. Maximum daily dose: 2000 mg.
500 mg orally once daily for 7 to 14 days
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 6-12 hours in hepatic impairment or overdose.
Terminal elimination half-life is 5-7 hours in healthy adults; prolonged to 20-40 hours in patients with severe hepatic impairment (Child-Pugh Class C).
Primarily metabolized in the liver via glucuronidation and sulfation; a minor pathway via CYP2E1 (and CYP1A2, CYP3A4) produces the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by glutathione.
Primarily metabolized by the cytochrome P450 system, mainly CYP3A4, to active metabolites such as 14-hydroxyclarithromycin.
Renal excretion of unchanged drug and glucuronide conjugate accounts for 90-95% of elimination; biliary/fecal elimination accounts for 5-10%.
Approximately 20-30% of the dose is excreted unchanged in urine, with the remainder as metabolites (primarily via biliary/fecal elimination). Renal clearance accounts for about 12% of total clearance.
10-25% bound to plasma proteins (albumin).
Approximately 70% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
0.9-1.1 L/kg; indicates extensive distribution into body fluids including CSF.
Volume of distribution is 3-4 L/kg, indicating extensive tissue penetration (e.g., lungs, sinuses, tonsils).
Oral: 75-90% (first-pass metabolism reduces from near 100% absorption); IV: 100%; Rectal: 70-85%.
Oral bioavailability is approximately 50% due to first-pass metabolism; food does not significantly affect the extended-release formulation.
GFR 30-50 m L/min: 500 mg every 8 hours. GFR 10-29 m L/min: 500 mg every 12 hours. GFR <10 m L/min: 500 mg every 24 hours.
Cr Cl <30 m L/min: 500 mg orally once daily or 250 mg twice daily. Cr Cl <30 m L/min not recommended for BIAXIN XL due to decreased clearance.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: 500 mg every 8 hours. Child-Pugh Class C: 500 mg every 12 hours.
Child-Pugh Class C: reduce dose by 50% or consider alternative therapy. Child-Pugh Class A or B: no adjustment necessary.
Children <2 years: not recommended. Children 2-12 years: 10-15 mg/kg/dose every 6 hours, maximum 60 mg/kg/day. Adolescents >12 years: same as adult.
Not approved for use in children less than 12 years of age. For children ≥12 years: same as adult dosing.
Initiate at 500 mg every 8 hours; increase interval if needed due to reduced renal function; consider maximum daily dose of 1500 mg.
Increased risk of QT prolongation. Monitor renal function and consider dose adjustment based on creatinine clearance. No specific dose adjustment is recommended solely for age.
Risk of severe liver injury; do not exceed 4,000 mg per day in adults or 2,000 mg per day in patients with liver disease. Concomitant use with other acetaminophen-containing products may lead to overdose.
No FDA boxed warning.
Hepatotoxicity, especially with doses >4 g/day or in patients with hepatic impairment; risk of acute generalized exanthematous pustulosis (AGEP); serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis); avoid use with alcohol or other hepatotoxic drugs.
Increased risk of cardiac arrhythmias (QT prolongation, torsades de pointes) in patients with pre-existing cardiac conditions or electrolyte abnormalities,Hepatotoxicity, including hepatic failure and jaundice,Exacerbation of myasthenia gravis symptoms,Increased risk of colchicine toxicity when used with P-glycoprotein inhibitors,Potential for drug interactions due to CYP3A4 inhibition
Hypersensitivity to acetaminophen or any component; severe hepatic impairment; use of other acetaminophen-containing products concurrently.
Hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic,Concomitant use with ergotamine or dihydroergotamine,Concomitant use with HMG-Co A reductase inhibitors that are extensively metabolized by CYP3A4 (e.g., lovastatin, simvastatin),Concomitant use with pimozide,History of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use,QTc prolongation or cardiac arrhythmia history (relative contraindication)
No significant food interactions. Alcohol increases risk of hepatotoxicity and should be avoided.
Take with food to enhance absorption and reduce GI intolerance. Avoid grapefruit and grapefruit juice as they may alter drug metabolism. No other significant food interactions.
ETHIRIL 500 (ethyl alcohol 500 mg) is not a standard drug; assuming it refers to ethanol. Teratogenic: First trimester: Increased risk of fetal alcohol spectrum disorders (FASD) including craniofacial abnormalities, growth deficiency, and neurodevelopmental deficits with chronic heavy use. Second trimester: Risk of spontaneous abortion and intrauterine growth restriction (IUGR). Third trimester: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome. No safe threshold established.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but maternal toxicity at high doses produced fetal malformations. Second and third trimesters: No known fetal risks from limited human studies; however, due to rare reports of pyloric stenosis in infants exposed to macrolides late in pregnancy, consider risk-benefit. Overall, use only if clearly needed.
Ethanol is excreted into breast milk. Milk-to-plasma ratio approximately 1.0. Peak milk levels occur 30-60 minutes after ingestion. Chronic heavy use may impair infant motor development and cause sedation. Avoid breastfeeding within 2 hours of alcohol consumption; excessive use contraindicated.
Clarithromycin is excreted into breast milk. M/P ratio is approximately 1.0 (based on total drug). Consider the potential for infant gastrointestinal effects (diarrhea, candidiasis) and theoretical risk of antibiotic-associated colitis. Compatible with breastfeeding with monitoring for adverse effects in the infant.
No therapeutic dosing; ethanol is not indicated in pregnancy. If used inadvertently, pharmacokinetic changes: increased volume of distribution may lower peak alcohol concentration, but no dose adjustment recommendation. Avoidance is critical.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes (increased volume of distribution, altered clearance) may occur, but clinical significance is not established. Use standard adult dosing with caution.
ETHRIL 500 (acetaminophen 500 mg) is hepatotoxic in overdose; maximum daily dose is 4 g in adults, but reduce to 2 g in patients with hepatic impairment, alcoholism, or malnutrition. Administer N-acetylcysteine for overdose within 8 hours for best efficacy.
BIAXIN XL (clarithromycin extended-release) is a macrolide antibiotic with a long half-life allowing once-daily dosing. It is a strong CYP3A4 inhibitor, increasing levels of many drugs including statins, warfarin, and oral contraceptives. Prolongs QT interval; avoid in patients with known QTc prolongation or concurrent use of other QT-prolonging agents. Common adverse effects include metallic taste and gastrointestinal upset. Monitor liver function in hepatic impairment.
Do not exceed 4 g (eight 500 mg tablets) per day.,Avoid alcohol while taking this medication.,Do not combine with other acetaminophen-containing products.,Seek immediate medical attention if overdose is suspected.,Take with or without food as needed.
Take with food to reduce stomach upset.,Do not crush or chew the tablet; swallow whole.,Complete the full course even if you feel better.,Avoid alcohol during treatment.,Inform your doctor about all medications, including OTC and herbal supplements, due to drug interactions.,Report symptoms of arrhythmia (dizziness, palpitations, fainting) or severe diarrhea.,May cause metallic taste; this is temporary.,Use alternate contraception if on oral contraceptives due to interaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ETHRIL 500 vs BIAXIN XL, answered by our medical review team.
ETHRIL 500 is a Macrolide Antibiotic that works by Acetaminophen (paracetamol) is a central analgesic and antipyretic agent whose exact mechanism is not fully understood but is thought to involve inhibition of cyclooxygenase (COX) enzymes in the brain, primarily COX-2, and activation of descending serotonergic pathways. It has weak peripheral anti-inflammatory activity.. BIAXIN XL is a Macrolide Antibiotic that works by Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ETHRIL 500 and BIAXIN XL depend on the specific clinical indication. These are both Macrolide Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ETHRIL 500 is: 500 mg orally every 6 hours as needed for pain. Maximum daily dose: 2000 mg.. The standard adult dose of BIAXIN XL is: 500 mg orally once daily for 7 to 14 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ETHRIL 500 and BIAXIN XL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ETHRIL 500 is classified as Category C. ETHIRIL 500 (ethyl alcohol 500 mg) is not a standard drug; assuming it refers to ethanol. Teratogenic: First trimester: Increased risk of fetal alcohol spectrum disorders (FASD) in. BIAXIN XL is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but maternal toxicity at high doses produced fetal ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.